Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 19/20 | 0.53 |
| ▸ | PPARG | P37231 | 17/20 | 0.53 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL4073279 | 1.00 | PPARA (0.53) | PPARAPPARGPPARD | |
| Arginine SCHEMBL4073313 | 0.93 | PPARG (0.44) | PPARAPPARGPPARD | |
| Arginine SCHEMBL4073310 | 0.93 | PPARG (0.44) | PPARAPPARGPPARD | |
| Arginine SCHEMBL4081908 | 0.92 | PPARG (0.51) | PPARAPPARGPPARD | |
| Arginine SCHEMBL4081910 | 0.92 | PPARG (0.51) | PPARAPPARGPPARD | |
| Arginine SCHEMBL4073136 | 0.92 | PPARG (0.47) | PPARAPPARGPPARD | |
| Arginine SCHEMBL4076709 | 0.92 | PPARG (0.47) | PPARAPPARGPPARD | |
| SCHEMBL4073286 | 0.90 | PPARG (0.44) | PPARAPPARG | |
| Arginine SCHEMBL4085902 | 0.89 | PPARA (0.51) | PPARAPPARGPPARD | |
| Arginine SCHEMBL4076394 | 0.89 | PPARA (0.51) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598293-B2 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | claimed |
| US-20070142470-A1 | COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LIMITED | 2007-06-21 | — | — | US | claimed |
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED | 2003-12-11 | — | — | US | claimed |
| US-7598293-B2 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070142470-A1 | COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LIMITED | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, PCSK9 | PPARA 182/4885PPARG 172/4885PPARD 155/4885 |
| US-20070142470-A1 | COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LIPA, PCSK9, GPR119 | PPARA 179/4885PPARG 169/4885PPARD 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.